KalVista Pharmaceuticals (NASDAQ:KALV) Insider Paul Audhya Sells 2,239 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul Audhya sold 2,239 shares of KalVista Pharmaceuticals stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $26.78, for a total value of $59,960.42. Following the sale, the insider directly owned 150,260 shares of the company’s stock, valued at approximately $4,023,962.80. The trade was a 1.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

KalVista Pharmaceuticals Stock Down 0.1%

KALV traded down $0.02 during trading on Wednesday, reaching $26.79. 2,466,702 shares of the stock traded hands, compared to its average volume of 2,436,684. The stock has a market cap of $1.43 billion, a price-to-earnings ratio of -7.74 and a beta of -0.12. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $9.83 and a fifty-two week high of $26.85. The company has a debt-to-equity ratio of 8.18, a current ratio of 5.17 and a quick ratio of 5.10. The stock’s 50-day simple moving average is $21.74 and its two-hundred day simple moving average is $17.54.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings data on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The company had revenue of $40.86 million during the quarter, compared to analysts’ expectations of $39.03 million. As a group, equities research analysts expect that KalVista Pharmaceuticals, Inc. will post -0.96 EPS for the current year.

Institutional Trading of KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in KALV. Parallel Advisors LLC lifted its position in shares of KalVista Pharmaceuticals by 45.8% during the 1st quarter. Parallel Advisors LLC now owns 1,876 shares of the specialty pharmaceutical company’s stock worth $38,000 after purchasing an additional 589 shares during the last quarter. Royal Bank of Canada lifted its position in shares of KalVista Pharmaceuticals by 137.0% during the 1st quarter. Royal Bank of Canada now owns 2,917 shares of the specialty pharmaceutical company’s stock worth $59,000 after purchasing an additional 1,686 shares during the last quarter. BNP Paribas Financial Markets lifted its position in shares of KalVista Pharmaceuticals by 47.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after purchasing an additional 1,292 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of KalVista Pharmaceuticals during the 3rd quarter worth about $55,000. Finally, Truvestments Capital LLC lifted its position in shares of KalVista Pharmaceuticals by 253.8% during the 4th quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock worth $76,000 after purchasing an additional 3,360 shares during the last quarter.

Wall Street Analyst Weigh In

KALV has been the subject of a number of analyst reports. Needham & Company LLC cut KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 30th. JonesTrading cut KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 21st. Leerink Partners cut KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Finally, Wall Street Zen cut KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, April 21st. Three research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $30.60.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.